The immunoregulation and clinical effect of Yupingfeng capsule combined with Seretide on patients with cough variant asthma
10.3760/cma.j.issn.1673-4246.2016.06.008
- VernacularTitle:玉屏风胶囊联合舒利迭对咳嗽变异性哮喘的免疫调节作用研究
- Author:
Shaolin LI
;
Yanfen FANG
;
Qiaolian LIU
;
Chunnan LI
- Publication Type:Journal Article
- Keywords:
Asthma;
Yupingfeng capsule;
Seretide;
Immunoregulation;
Outcome assessment
- From:
International Journal of Traditional Chinese Medicine
2016;38(6):512-514
- CountryChina
- Language:Chinese
-
Abstract:
Objective To detect the immunoregulation and clinical effect ofYupingfeng capsule combined with Seretide on patients with cough variant asthma (CVA).Methods CVA Patients were randomly divided into the Seretide control group (n=54) andYupingfeng capsule combined with Seretide group (n=54). Seretide group received inhaled Seretide. Combined traditional Chinese medicine group received Seretide and Yuping Feng capsule. Two groups were treated for 12 weeks. The IL-17, IL-10 and IL-6 expression was detected by ELISA analysis. The clinic effect rate and adverse events were compared.Results After treatment, compared with the Seretide group, the expression of IL-17 (18.72 ± 4.26 ng/mlvs. 26.17 ± 5.58 ng/ml;t=2.462,P<0.05) and IL-6 (21.58 ± 4.12 ng/mlvs. 30.66 ± 6.27 ng/ml;t=2.523,P<0.05) were significantly lower in combined traditional Chinese medicine group than that in Seretide group; and IL-10 (15.56 ± 2.74 ng/mlvs. 12.25 ± 2.81 ng/ml;t=2.244, P<0.05) was significantly higher in combined traditional Chinese medicine group. The daytime (1.12 ± 0.26 vs.1.42 ± 0.33,t=2.283) and night time cough score (1.24 ± 0.28vs. 1.52 ± 0.37,t=2.291) in combined traditional Chinese medicine group was significantly lower than that in Seretide group (P<0.05). The clinic effect rate (92.6%vs. 77.8%,χ2=2.438) in combined traditional Chinese medicine group was significantly higher than that in Seretide group (P=0.037).ConclusionYupingfengcapsule combined with Seretide can decrease IL-17 expression and increase IL-10 expression to inhibit inflammatory reaction in CVA patients, and showed significantly higher clinical effect rates.
